From our Oct. 15 issue: One...
Learn more about this primarily cancer-driven...
The guiding principle is global information...
Which firms are ripe for the...
These industry players have had no shortage of ideas when it comes to biotech businesses. [© escova - Fotolia.com]
At present: David H. Koch Institute Professor at MIT, one of 14 to receive the institute’s highest faculty honor.
Degrees: Cornell University, B.S. in chemical engineering, 1970; MIT, Sc.D. in chemical engineering, 1974.
At present: Venture partner, CMEA Capital, 2010–present; Managing director and Chief Medical Officer, Velocity Pharmaceutical Development.
Degrees: Colorado College, B.S. in Chemistry; Duke University School of Medicine, M.D. and Ph.D., from Medical Scientist Training Program, Molecular and Cell Biology.
miRagen—Co-founder; President and CEO; member of the Board of Directors.
Dharmacon—Scientific co-founder; Executive VP for Research and Operations and General Manager. Company founded 1995 to provide RNA oligonucleotides, small interfering RNA (siRNA), and related RNAi products and technologies. Acquired in 2004 by Fisher Scientific International, now ThermoFisher.
Degrees: University of Wisconsin-Madison, B.S. in Biochemistry; University of Colorado at Boulder, Ph.D. in Chemistry.
Degrees: Wake Forest University, B.A. in Chemistry and Biology; Ph.D. in Biochemistry; honorary doctorate.
Degrees: Sarah Lawrence College, B.A.; University of Pennsylvania School of Veterinary Medicine, V.M.D.; Cornell University, Ph.D. in physiology.
Degrees: University of Illinois at Chicago, Ph.D. in Molecular Biology, 1995,
Degrees: University of Montevideo, B.Sc., 1941; Ph.D. in Biochemistry from University of Rochester, 1949.
When do you think an Ebola vaccine will be available for the general public?
Be sure to add email@example.com
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2014 Genetic Engineering & Biotechnology News All Rights Reserved